etrasimod: Clinical Trials

7 trials of etrasimod, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 terminated, 1 active not recruiting, 1 unknown. 7 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 37Completed 3, Terminated 2, Active not recruiting 1, Unknown 1
Phase 22Terminated 2

Follow etrasimod: new trials by email Literature Review of etrasimod trials Research Report on etrasimod

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection
etrasimod, Placebo - Atopic Dermatitis, Atopic Dermatitis, Unspecified
Phase 2 / Phase 3TerminatedPfizer582023-01-182025-05-08
Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)
Etrasimod, Placebo - Ulcerative Colitis
Phase 3CompletedPfizer422020-12-252023-10-16
Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis
Etrasimod, Placebo - Ulcerative Colitis
Phase 3CompletedArena Pharmaceuticals3542020-09-152022-12-21
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
Etrasimod, Placebo - Crohn's Disease
Phase 2 / Phase 3TerminatedPfizer3792020-01-062026-07-01
A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis
Etrasimod, Placebo - Moderately to Severely Active Ulcerative Colitis
Phase 3UnknownEverstar Therapeutics Limited3412019-09-102024-01-09
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
Etrasimod - Ulcerative Colitis
Phase 3Active not recruitingPfizer8962019-09-052026-11-06
Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
Etrasimod, Placebo - Ulcerative Colitis
Phase 3CompletedArena Pharmaceuticals4332019-06-132022-12-20

Conditions studied

Colitis, Ulcerative (4)  ·  Crohn Disease (1)  ·  Dermatitis, Atopic (1)  ·  Eczema (1)  ·  Inflammatory Bowel Diseases (1)

Sponsors

Pfizer (4)  ·  Arena Pharmaceuticals (2)  ·  Everstar Therapeutics Limited (1)

Countries

Canada (5)  ·  Czechia (5)  ·  Poland (5)  ·  United States (5)  ·  Argentina (4)  ·  Australia (4)  ·  Austria (4)  ·  Belarus (4)  ·  Belgium (4)  ·  Bulgaria (4)  ·  Chile (4)  ·  Croatia (4)  ·  Denmark (4)  ·  France (4)  ·  Georgia (4)

Top investigators

Arena CT.gov Administrator (2)  ·  Kaichun Wu (1)

Results publications

PMID 39778975, PMID 42248437, PMID 36871574, PMID 38613425, PMID 38700040, PMID 38877972, PMID 39089519, PMID 39306680, PMID 39326009, PMID 39526078, PMID 39671695, PMID 39878434, PMID 39891572, PMID 40036804, PMID 40184206, PMID 40618942, PMID 40889900, PMID 41655066, PMID 42523912, PMID 42864953, PMID 39575597, PMID 41043449, PMID 42542725, PMID 42848715

NIH funding

2018 (2)